PAREXEL Launches Active Tracking Service for Monitoring and Managing Temperature-Controlled Investigational Medicinal Products
October 06 2016 - 8:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, today announced the
launch of its Active Tracking service. The service follows Good
Distribution Practice (GDP) requirements by providing
biopharmaceutical companies with near real-time temperature and
location monitoring of investigational medicinal products (IMPs)
from central distribution centers to clinical trial sites.
An increasing number of medicinal products require a
temperature-controlled supply chain to maintain product integrity
during transport, including approximately 75 percent of biological
drugs, 10 to 15 percent of small molecule therapies, 100 percent of
vaccines, and a large percent of biologic samples and diagnostic
tools.1 Temperature deviations and shipment delays can impact
patient safety, create patient retention issues, and cause
additional manufacturing and shipment costs.
Supported by PAREXEL’s Clinical Trial Supply & Logistics
global depot and service network, PAREXEL’s Active Tracking service
utilizes supply chain monitoring technology to detect incidents,
such as shipment delays, shipment diversions, and temperature
deviations. When combined with PAREXEL ClinPhone® RTSM interactive
response technology (IRT), temperature and location data is
automatically sent in near real-time to clinical trial sites for
assessment. This integration enables greater automated preventive
or remedial actions, such as release, quarantine, and automatic
re-order of temperature-controlled products, simplifying
temperature management for sites and sponsors.
“In the past, an investigational site had to wait until it
received a shipment and downloaded the data from the temperature
logger to find out if a drug’s temperature had been compromised,”
said Sanjay Vyas, Corporate Vice President, Clinical Trial Supplies
& Logistics, PAREXEL. “With PAREXEL’s Active Tracking service,
we can monitor IMPs from packaging at our depots through transit to
clinical trial sites, in near real-time. This innovation in
clinical supply chain management allows us to quickly respond to
any temperature complications, which can reduce safety risks for
patients as well as manufacturing and shipment costs for
clients.”
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 84 locations in 51 countries around the
world, and had approximately 18,600 employees in the fourth
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
1 Visiongain report, “Clinical Trial Supply and Logistics: World
Industry and Market Outlook 2015-2025,” 2015.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161006005025/en/
PAREXEL InternationalCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorPAN CommunicationsJenny
Gardynski, +1 617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024